AHSP

Across TCGA pan-cancer cohorts, AHSP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AHSP data layer compared with 17 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AHSP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHSP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where AHSP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.961	0.590	<.001	37	view →
LUAD	DFS	Tertile	All	0.905	0.527	.024	5	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.915	.033	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
GBM	OS	Quartile	All	0.568	0.278	.049	2	view →
LSCC	DFS	Quartile	II,III,IV	0.468	0.797	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AHSP–CCRCC (DFS)

Open the CCRCC breakdown →